Navigation Links
Scientists show that HIV drugs can also target tropical parasites
Date:5/2/2011

Scientists have discovered that drugs used to treat HIV may also one day become lifesaving drugs targeted at parasitic diseases such as leishmaniasis and malaria. According to new research published in The FASEB Journal (http://www.fasebj.org), scientists have identified the target of action for some anti-HIV drugs with known abilities to kill serious pathogenic parasites. While scientists have long known that these HIV drugs can kill parasites, exactly how they work was previously unknown. Researchers discovered that a particular protein called Ddi 1 from Leishmania parasites is sensitive to anti-HIV inhibitors. This research could one day significantly change the treatment of parasitic diseases.

"People in developing countries can be exposed to parasitic diseases such as malaria and leishmaniasis that can kill millions of people, so new and effective drugs are urgently needed to combat these infections," said Colin Berry, Ph.D., a researcher involved in the work from the Cardiff School of Biosciences at Cardiff University in Cardiff in the United Kingdom. "The use of existing anti-HIV agents has indicated that there is a potential target in some parasites and by identifying the protein responsible, we hope to exploit this weakness in the parasite to develop new and effective therapeutics to combat these devastating diseases."

Scientists studied yeast that lacked the Ddi 1 protein and found that high levels of proteins were secreted. The addition of the Leishmania Ddi 1 protein returned the yeast to normal low secretion levels until HIV proteinase inhibitors were added. These inhibitors blocked the ability of Leishmania Ddi 1 to reduce secretions and showed that the Ddi 1 protein interacted with the drugs. Additionally, when researchers used human Ddi 1, they identified drugs that were good at blocking the activity of the Leishmania protein, but which were much weaker against the human equiva
'/>"/>

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
Source:Eurekalert

Page: 1 2

Related medicine news :

1. March of Dimes awards $250,000 prize to scientists who explained human sex chromosomes
2. Scientists create stable, self-renewing neural stem cells
3. Musicians and scientists to research mind and music at Rice University conference
4. Scientists Discover How Peppermint Soothes Gastric Pain
5. Scientists develop compound that effectively halts progression of multiple sclerosis
6. Scientists Spot Key Gene Mutations in Melanoma
7. Illusion can halve the pain of osteoarthritis, scientists say
8. Berkeley Lab scientists find that normal breast cells help kill cancer cells
9. Artery Plaque Forms in Short Time Span, Scientists Say
10. Scientists Complete Detailed Map of Human Brain
11. Feinstein scientists identify abnormal disease pathway in dystonia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Bronx, NY (PRWEB) , ... September 01, 2015 , ... ... for 86 children and teenagers, from ages 6-18. Calvary’s Camp Compass® has taken place ... camp staff included 65 adult counselors, some of whom work for Calvary, and two ...
(Date:9/1/2015)... ... September 01, 2015 , ... Consumers overwhelmingly prefer to have ... Surgery, according to a new survey that also offers insight on why that ... – which reflects views on cosmetic medical treatments and ratings for 10 specific ...
(Date:9/1/2015)... ... September 01, 2015 , ... Plaza OBGYN in ... MonaLisa Touch® , an innovative vaginal health laser procedure that prevents and resolves ... treatment for atrophic vaginitis, a condition that causes vaginal dryness, pelvic discomfort, painful ...
(Date:9/1/2015)... ... September 01, 2015 , ... With former IBMers among its ... disciplines since its inception more than 35 years ago. A pilot program begun by ... teachers - and, not just those intent on pursuing careers in these fields. The ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... Nelson, D.O., has joined its medical management team as an Associate Medical Director. ... all sizes and types in the U.S. and abroad. , Dr. Nelson ...
Breaking Medicine News(10 mins):Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 2Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 3Health News:Survey: Consumers Prefer ASDS Members 2Health News:Survey: Consumers Prefer ASDS Members 3Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 2Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 3Health News:Inmar Announces Program to Fuel Student Passion for STEM – with an Unconventional Twist 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 3
... (LTR) at the LSU Health Sciences Center New Orleans ... million contract over seven years by the National Cancer ... Epidemiology and End Results) Program-designated cancer registry. There are ... States., "The SEER Program is the most authoritative source ...
... if therapeutic anticancer vaccines, which are designed to boost ... developed. For example, the viruses used to deliver the ... targeted by the patient,s immune system, inducing neutralizing and ... by Michael Morse, at Duke University Medical Center, Durham, ...
... By Amanda Gardner HealthDay Reporter , MONDAY, Aug. ... to fashion a therapeutic vaccine that appears to attack a ... required tumor-fighting immune response in early human trials, but only ... urged caution. "They were able to generate an immune ...
... N.C., Aug. 2 - Merz Pharmaceuticals today announced that ... has approved Xeomin (incobotulinumtoxinA), a botulinum toxin type ... or blepharospasm. According to an epidemiology study conducted in ... cervical dystonia and blepharospasm, is estimated at 295 per ...
... able to significantly reduce the radiation dose associated with ... one day dose optimization workshop provided by the Royal ... supported by the local state health department, according to ... Journal of the American College of Radiology (www.jacr.org). ...
... A study in the Aug. 1 issue of the journal ... age male infants are easier to arouse than females during quiet ... no significant gender differences in arousability. The results suggest that ... may not reflect a pre-existing vulnerability involving arousal responses. Results ...
Cached Medicine News:Health News:LA Tumor Registry at LSUHSC awarded $12 million SEER contract by NCI 2Health News:LA Tumor Registry at LSUHSC awarded $12 million SEER contract by NCI 3Health News:Vaccine Shows Some Promise Against Advanced Cancers 2Health News:FDA approves Merz Pharmaceuticals' Xeomin (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm 2Health News:FDA approves Merz Pharmaceuticals' Xeomin (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm 3Health News:FDA approves Merz Pharmaceuticals' Xeomin (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm 4Health News:SIDS surprise: Study finds that infant boys are more easily aroused from sleep than girls 2Health News:SIDS surprise: Study finds that infant boys are more easily aroused from sleep than girls 3
(Date:9/1/2015)... SPRINGDALE, Ark. , Sept. 1, 2015 NOWDiagnostics Inc., ... completed its acquisition of ZBx Corporation of Canada ... to its vision of a world where people have ... NOWDiagnostics manufactures and sells a line of unique blood-based ... simple-to-use, highly accurate tests for a variety of ailments ...
(Date:9/1/2015)... 1, 2015 UT Southwestern Medical Center President ... members joined U.S. Representatives Michael C. Burgess , ... discussion on the 21 st Century Cures Act, ... considered by the United States ... Academy of Sciences members, department chairs, center directors, and ...
(Date:9/1/2015)... Sept. 1, 2015  Results from an interim analysis ... that 5g of idarucizumab enabled emergency surgery to ... treated with dabigatran (Pradaxa ® dabigatran etexilate ... effect of dabigatran enabled patients to be urgently ... of 1.7 hours between administration of idarucizumab and ...
Breaking Medicine Technology:NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 2NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 3U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 2U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 3U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 4U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 5New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 2New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 3New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 4New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 5New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 6New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 7New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 8New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 9
... in wake of AHA-presented data , ... a clinical trial suggesting rosuvastatin may lower the cardiovascular risk ... statin use in older adults, according to a national poll ... the online poll conducted by medical news site MedPage Today ...
... FRANCISCO, Calif., Nov. 25 Poniard,Pharmaceuticals, Inc. (Nasdaq: ... on,innovative oncology therapies, announced today that it will ... in order to allow,the Company to focus its ... product candidate, and to support the initial commercialization ...
Cached Medicine Technology:Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 2Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 3
... Right Solution For Your Tracheostomy Care Needs, ... tray features the latest components for efficient ... control task. Designed by clinicians, these latex-free ... each patient and caregiver. All of our ...
... Right Solution For Your Tracheostomy Care Needs, ... tray features the latest components for efficient ... control task. Designed by clinicians, these latex-free ... each patient and caregiver. All of our ...
... alternate care facilities with a wide ... offer the finest in nursing convenience ... guidance of experienced nursing personnel, these ... is required for efficient and quick ...
... alternate care facilities with a wide ... offer the finest in nursing convenience ... guidance of experienced nursing personnel, these ... is required for efficient and quick ...
Medicine Products: